Patent intelligence · US
US 11530236
CD73 inhibitors
CD73 inhibitors
Patent details — US 11530236
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 20, 2022
- Expiration
- Dec 15, 2042
- Applicant
- ORIC PHARMACEUTICALS, INC.
- Claims
- 25
- CPC classes
- A61K, A61K45/06, A61P, A61P35/00
Quick answer
US 11530236 (CD73 inhibitors) is held by ORIC PHARMACEUTICALS, INC.. Status: granted. Granted Dec 20, 2022. Expires Dec 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ORIC PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K45/06, A61P, A61P35/00
More from ORIC PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12312339
Polo like kinase 4 inhibitors
granted -
US 12239729
TRPV3 agonists for the treatment of skin conditions
granted -
US 12054556
Anti-PD-L1 antibody and use thereof
granted -
US 12018043
CD73 inhibitors
granted -
US 12005080
Method for promoting proliferation of immune cells
granted -
US 11993655
Anti-PD-L1 antibody and use thereof
granted -
US 11858915
Polo like kinase 4 inhibitors
granted -
US 11807658
CD73 inhibitors
granted
Frequently asked questions
What is US patent 11530236?
US 11530236 (CD73 inhibitors) is held by ORIC PHARMACEUTICALS, INC.. Status: granted. Granted Dec 20, 2022. Expires Dec 15, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11530236?
ORIC PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 52 pharmaceutical patents for this assignee.
When does US 11530236 expire?
Our index shows an expiration date of Dec 15, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.